<DOC>
	<DOCNO>NCT00868283</DOCNO>
	<brief_summary>The study investigate clinical efficacy safety 10-day course therapy daily intravenous administration 30mL Cerebrolysin base comparison Placebo patient acute ischemic stroke . 1070 patient randomize trial 2 parallel group , one receiving Cerebrolysin , control group receive Placebo . Study drug give daily intravenous infusion 10 consecutive day . Acetylsalicylic acid give orally , daily throughout study duration 90 day basic treatment . The clinical observation period patient 3 month include six clinical evaluation visit Baseline ( day 1 ) study day 2 , 5 , 10 , 30 90 .</brief_summary>
	<brief_title>The Safety Efficacy Cerebrolysin Patients With Acute Ischemic Stroke</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Cerebrolysin</mesh_term>
	<criteria>Age 18 85 year Focal neurological deficit Clinical diagnosis acute hemispheric ischemic stroke CT MRI result compatible clinical diagnosis acute hemispheric stroke NIH Stroke Scale Score 6 22 , inclusive Functionally independent prior stroke prestroke Rankin Score 0 1 Randomization first treatment trial medication within 12h stroke onset Informed consent give patient and/or patient 's legally acceptable representative Evidence CT/MRI acute chronic intracerebral hemorrhage , SAH , AVM , cerebral aneurysm , neoplasm Signs herniation , increase intracranial pressure likely etiology brain ischemia baseline CT scan Patients substantial decrease consciousness alertness time randomization , define score 2 one NIH Stroke Scale question 1a . Neurological sign symptom improve rapidly screen likely resolve completely within 24h Severe coexist systemic disease significantly limit life expectancy Systolic blood pressure 220 mmHg diastolic blood pressure 120 mmHg repeat measurement ( interval 30 min ) prior study entry Severe congestive heart failure presentation acute myocardial infarction study entry Epilepsy epileptic seizure onset stroke Preexisting disorder condition would impair interpretation neurological assessment ( eg . severe dementia , severe psychiatric illness , etc ) . Concomitant treatment neuroprotective nootropic drug ( e.g . piracetam , citicoline , investigational neuroprotective substance ) Patients tolerate contraindication aspirin Cerebrolysin treatment Concomitant treatment substance dilative effect blood vessel like naftidrofuryl , cinnarizine , flunarizine nimodipine Pregnancy lactation period ; woman childbearing potential negative pregnancy test require Participation clinical trial investigational drug past 4 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>